SCHAUMBURG, Ill., Aug. 18, 2011 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of vecuronium bromide for injection, a neuromuscular blocking agent, in 10 and 20 mg single-use vials. According to 2010 IMS data, the U.S. vecuronium bromide market approximated $10 million. As with all products in Sagent's portfolio, vecuronium bromide for injection features the company's PreventIV Measures packaging and labeling designed to aid in the reduction of medication errors.
